GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
CompareDulaglutide vs Orforglipron
Ingredient comparison

Dulaglutide vs Orforglipron

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Every cash quote was checked on or after Sep 26, 2026.Data feeds · Oct 3, 2026 UTC
OverviewDirect evidenceCash pricesTrial resultsChange comparison
Dulaglutide vs Orforglipron: overview
CompareDulaglutideOrforglipron
Brands

Dulaglutide

Trulicity

GLP-1

Orforglipron

Foundayo

Small-molecule GLP-1

Route & frequency

Dulaglutide

Subcutaneous injection

Once weekly

Orforglipron

What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Dulaglutide vs Orforglipron: sourced cash quotes
CompareDulaglutideOrforglipron
Advertised entry price

Dulaglutide

from $389/28 days

Trulicity single-dose pens

LillyDirect (Eli Lilly)

self-pay, four weekly pens; published starting rate at each dose

28-day supply

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Dulaglutide vs Orforglipron: individual trial outcomes
CompareDulaglutideOrforglipron
Weight change

Dulaglutide

≈−4% (-4.6 kg (~4%) at 36 wks · AWARD-11 · 4.5 mg weekly (Trulicity))

-4.6 kg (~4%) at 36 wks

AWARD-11

4.5 mg weekly (Trulicity)

Approximation from kilograms; see trial methods

Check the product label

Approved uses & full records

Dulaglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

142 registered ingredient studies. Count checked Oct 3, 2026. Research activity, not a measure of evidence quality.

Open full record

Orforglipron

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

53 registered ingredient studies. Count checked Oct 3, 2026. Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Which costs less: Dulaglutide or Orforglipron?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Other comparisons
Semaglutide vs DulaglutideSemaglutide vs OrforglipronTirzepatide vs DulaglutideTirzepatide vs OrforglipronLiraglutide vs DulaglutideLiraglutide vs Orforglipron

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier

Oral tablet (any time of day, no food or water restriction)

Once daily

FDA shortage report

Dulaglutide

National reporting does not confirm stock at your pharmacy.

Coverage & source records

Orforglipron

National reporting does not confirm stock at your pharmacy.

Coverage & source records

≈ $416.79 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

self-pay, four weekly pens; published starting rate at each dose

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. Four once-weekly pens cover 28 days.

28-day supply

Orforglipron

from $149/mo

Foundayo (LillyDirect self-pay)

LillyDirect (Eli Lilly)

self-pay cash, lowest dose; ~$25/mo with commercial coverage

30-day supply

$149 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

self-pay cash, lowest dose; ~$25/mo with commercial coverage

The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.

30-day supply

At the named trial dose

Dulaglutide

from $389/28 days

Trulicity single-dose pens

At 4.5 mg

LillyDirect (Eli Lilly)

Published price at 4.5 mg

28-day supply

≈ $416.79 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

Published price at 4.5 mg

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. Four once-weekly pens cover 28 days.

The same starting rate is published for 0.75, 1.5, 3 and 4.5 mg. Taxes and additional fees may apply.

28-day supply

Orforglipron

$299/mo

Foundayo (LillyDirect self-pay)

At 17.2 mg

LillyDirect (Eli Lilly)

Published price at 17.2 mg

30-day supply

$299 per 30 days at this quoted rate

Checked Sep 30, 2026

Price conditions

Published price at 17.2 mg

The first oral small-molecule GLP-1 pill for weight loss; FDA-approved April 2026. LillyDirect self-pay ladder: $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg), $299 (14.5 and 17.2 mg with a 45-day refill, else $349); the 2.5 mg and 5.5 mg doses are temporarily $149 and $199 through Dec 31, 2026.

Self-Pay Journey price for 14.5 mg and 17.2 mg with a refill within 45 days; regular price $349. Eligibility, additional taxes and fees may apply.

30-day supply

Explore product prices

Dulaglutide

All Dulaglutide offers

Orforglipron

All Orforglipron offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Study context

A diabetes trial; weight loss is a secondary endpoint, so the effect is modest.

Orforglipron

−11.2% (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; 36 mg capsule-equivalent in ATTAIN-1))

-11.2% at 72 wks

ATTAIN-1

17.2 mg daily (Foundayo; 36 mg capsule-equivalent in ATTAIN-1)

Accounts for treatment discontinuation

Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

HbA1c change (percentage points)

Dulaglutide

−1.9 pp (-1.9% at 36 wks · AWARD-11 · HbA1c change in percentage points)

-1.9 percentage points at 36 wks

AWARD-11
Study context

A diabetes trial; weight loss is a secondary endpoint, so the effect is modest.

Orforglipron

−1.5 pp (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points)

-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1)

ACHIEVE-1
Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

Adverse events

Dulaglutide

Stopped treatment for adverse events

8.5% (8.5% vs 6.0% on the 1.5 mg comparator (no placebo arm) · AWARD-11 (4.5 mg, type 2 diabetes))

Reported nausea

17.3% (Nausea in the drug arm · AWARD-11 (4.5 mg, type 2 diabetes))

AWARD-11 (4.5 mg, type 2 diabetes)

a type 2 diabetes trial with no placebo arm (the contrast is vs dulaglutide 1.5 mg), so it is not one-to-one with the obesity-trial figures

Orforglipron

Stopped treatment for adverse events

10.3% (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))

Reported nausea

33.7% (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))

ATTAIN-1 (36 mg, 72 wks, obesity)